QuickView for HLH domain binding (biogroup)

1. Chemotherapeutic treatment of MCF7, ZR-75-1, HME-CC, and ME16C cell lines
2. Liver gene expression of disease-prone and obese-resistant mice strains on high fat diets
3. L1000 CMAP - Hepatocellular carcinoma Hep G2 cells with shRNA-mediated gene knockdown (2 of 2)
4. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
5. L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens

1. The semidominant Mi(b) mutation identifies a role for the HLH domain in DNA binding in addition to i…

There were no clinical trials for HLH domain binding